Four ways a peptide comes apart
Reversed-phase chromatography runs in an organic, acidic mobile phase that dissociates most non-covalent aggregates on the way to the detector.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Analytics
A brief and unromantic tour of the interface between a liquid sample and a vacuum.
Ask a laboratory which ionisation source produced a spectrum and you learn a great deal about the spectrum before you have looked at it. Electrospray on a modern instrument will give a peptide of four thousand daltons a family of multiply charged ions and a mass accuracy in the low parts per million. A linear MALDI time-of-flight will give a single predominantly singly charged ion and an accuracy measured in hundreds of parts per million. Both can answer the question, is this the right compound. Only one of them can answer the question, is this the right compound and nothing very close to it.
It is worth being exact about what a mass spectrometer does, because the imprecision propagates. The instrument generates ions from a sample, separates them according to the ratio of their mass to their charge, and counts them at a detector. The horizontal axis of every spectrum is mass-to-charge, conventionally written m/z and expressed in thomsons or in dimensionless units depending on the vendor’s software. Nothing is weighed. Nothing is measured against a reference mass in the sense that a balance measures against a calibration weight.
What follows from this is that every molecular weight on every certificate of analysis in this market is a calculated quantity, derived from a measured m/z by assigning a charge and subtracting the mass contribution of whatever adducted to the molecule to give it that charge — usually protons, sometimes sodium, occasionally potassium or ammonium. The assignment is normally straightforward and normally correct. It is nonetheless an assignment, and when it goes wrong it goes wrong by an integer factor, which is the kind of error that produces confident nonsense rather than a plausible discrepancy.
The practical consequence for a reader is a habit: when a mass figure appears, ask what was observed and what was inferred. A report that gives both — the m/z, the charge, and the derived neutral mass — has answered the question before it was asked.
Electrospray ionisation works by pumping a solution of the analyte through a fine capillary held at a potential of a few kilovolts relative to the instrument’s entrance. The liquid emerging from the tip forms a cone and then a jet of charged droplets. As solvent evaporates the droplets shrink, the charge density on their surfaces rises, and at the point where electrostatic repulsion exceeds surface tension they fission into smaller droplets. Repeat this enough times and what is left is a bare, charged analyte ion in the gas phase.
Because the charge is acquired in solution and retained through desolvation, a peptide with several basic residues will carry several protons, and the population of ions reaching the analyser is distributed across charge states. This is the defining characteristic of electrospray spectra and the reason they look bewildering to a first-time reader: a single pure compound produces four or five prominent peaks, none of them at the molecular weight.
The distribution is not noise. It carries information about the number of accessible basic sites and about the conformational state of the molecule in solution, and it shifts predictably with mobile-phase composition and pH. It also has a practical advantage that matters for identity work: dividing the mass by three or four brings a large peptide into the range where instruments achieve their best resolving power and accuracy.1
What a mass measurement cannot see is the more useful list. Deamidation shifts the mass by one dalton and is invisible on most instruments in use here. Isomerisation and racemisation shift it by nothing at all. Aggregates do not survive the ionisation and are simply absent from the spectrum.
A matching mass has established that the vial contains something of the same elemental composition. That is not identity, and it is not close.
The standing rule in this departmentMatrix-assisted laser desorption ionisation takes a different route. The peptide is mixed with a large molar excess of a small organic compound that absorbs strongly at the laser wavelength — α-cyano-4-hydroxycinnamic acid and sinapinic acid are the usual choices for peptides and proteins respectively — and the mixture is dried on a metal target. A pulsed ultraviolet laser strikes the crystal, the matrix absorbs the energy, and a plume of matrix and analyte is ejected into the vacuum with the analyte largely intact and mostly singly protonated.
Two consequences follow. First, MALDI spectra are simple: one predominant ion per compound, at the molecular weight plus one proton, which makes them easy to read and easy to print on a certificate. Second, MALDI is markedly more tolerant of salts, buffers and heterogeneous samples than electrospray, which is why it survives in routine synthesis monitoring where electrospray would require a chromatographic clean-up first.
The trade-offs are equally real. The matrix produces intense chemical background below roughly a thousand daltons, which obscures small fragments. Ion yield varies between compounds and between spots on the same target, making MALDI a poor quantitative technique. And the achievable mass accuracy on a linear instrument at peptide molecular weights is measured in hundreds of parts per million unless a reflectron and delayed extraction are in use.2
| Element of the identity claim | Certificates stating it (of 20) |
|---|---|
| A mass spectrometric identity test was performed | 14 |
| Both observed and theoretical mass given | 8 |
| Instrument or analyser class named | 6 |
| Ionisation source or mode named | 5 |
| A spectrum reproduced in the document | 5 |
| Charge state of the reported ion stated | 4 |
| Monoisotopic or average convention stated | 3 |
| An acceptance tolerance stated | 3 |
| Peptide mapping or MS/MS performed | 1 |
| Counts are of the most recent certificate supplied to the Journal by each of the twenty companies in the dossier programme as at the last quarterly cycle. A company is credited where the element appears anywhere on the document or on an attached laboratory report. No inference about material quality should be drawn from a documentary count. | |
The choice between the two techniques is not a matter of quality but of question. A synthesis chemist watching a coupling proceed wants a fast, salt-tolerant check that the chain has grown by the expected residue, and MALDI on a bench instrument answers that in minutes. An analytical laboratory asked whether a submitted vial contains the labelled compound and nothing closely related to it needs the resolving power and the accuracy that electrospray into a high-field analyser provides, coupled to a chromatographic separation so that species which co-elute can at least be assigned to retention times.
Both appear in this market, and reports rarely distinguish them. That matters because the two techniques have different blind spots. MALDI can induce loss of labile modifications during desorption, so a phosphorylated or otherwise fragile species may be under-represented. Electrospray suppresses ionisation of some analytes in the presence of others, so a minor component of a mixture may be absent from a spectrum in which it is genuinely present.
A certificate stating the source therefore tells a reader which class of error to consider. The Journal has stopped asking suppliers for more testing and started asking them for this line instead, on the grounds that it costs nothing and changes what the existing test can be said to support.
Where a peptide map is performed, the headline output is a coverage figure: the percentage of residues in the expected sequence accounted for by identified fragments. Ninety-five per cent coverage sounds close to complete and is worth interrogating, because the five per cent that is missing is not randomly located. Very short fragments elute in the solvent front and are lost. Very hydrophobic fragments retain on the column. Regions between closely spaced cleavage sites produce peptides too small to identify unambiguously.
The consequence is that the uncovered fraction tends to sit in the same places for a given protease and a given sequence, which means a laboratory reporting ninety-five per cent coverage in run after run has ninety-five per cent coverage of a specific ninety-five per cent. A second digest with a different enzyme is the conventional remedy, and a report that used two orthogonal proteases is doing something a report using one cannot.
For a reader assessing a document, the useful questions are which enzyme, what coverage, and whether the uncovered residues are identified. A map that names the missing stretch has told you where the residual uncertainty lives. A map that reports a percentage alone has told you a number whose meaning depends on information it withheld — which is, in a different guise, the same complaint this department makes about purity figures reported without a gradient.
Instrument class belongs on the report because the same result means different things on different hardware. A unit-resolution quadrupole and a high-resolution time-of-flight instrument can both report a match, and only one of them could have seen a species a dalton away.
This publication applies one rule to every identity claim it reports, and it is worth stating in isolation because it governs the rest. A mass measurement supports a statement about composition. Only a fragmentation or mapping experiment supports a statement about sequence. Where a source says identity was confirmed, we report that a mass was measured, unless we have seen evidence of the second kind.
The rule has consequences we accept. It makes our coverage read as more sceptical than the underlying documents, because the documents claim more than they establish. It occasionally irritates laboratories which have in fact done sequence-level work and have simply not printed it, and the remedy there is a two-line email which we are glad to receive. And it means we cannot describe any research-grade vial in this market as sequence-confirmed, because on the evidence available to us almost none are.
What the rule is not is an accusation. Nothing in this article suggests that vendors are selling material other than what they label, and the Journal has no evidence of that in respect of any company it covers. The claim is narrower and, we think, harder to argue with: the documentation in general circulation does not have the discriminating power that the language on it implies, and the gap between the two is where every avoidable dispute in this market begins.
Readers who take one thing from this piece should take the arithmetic. Isotope spacing is one over the charge. Deamidation is one dalton, oxidation is sixteen, and stereochemical inversion is nothing at all. A tolerance of ±1 dalton on a four-thousand-dalton peptide is two hundred and forty parts per million and excludes almost nothing worth excluding. Those four facts are sufficient to read most of the identity claims in circulation, and they fit on the back of an envelope.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
A practical note from a service bench. Sodium and potassium adducts are the commonest reason a first spectrum looks wrong, and they come from the glassware and the water rather than from the sample. Before anybody concludes a peptide is not what it says it is, they should check whether the offset is twenty-two.
— V. Bhattarai, Kathmandu
Twenty-two for sodium in place of a proton, thirty-eight for potassium. It is the first thing an experienced analyst checks and the last thing a buyer reading a spectrum knows to look for.
Adducts deserve a paragraph. Sodium and potassium are everywhere in glassware and buffers, they shift the observed mass by amounts that look meaningful, and an analyst who is not expecting them can report a modification that is really a salt. It is the most common false positive I see in this trade.
— L. Silveira, Belo Horizonte
The monoisotopic against average distinction is the one I spend most time explaining. Below about two kilodaltons the monoisotopic peak is the one you can see and the one you should quote. Above it the isotope envelope broadens until the average is the honest description, and a certificate quoting a monoisotopic mass for a large peptide is quoting a peak nobody resolved.
— A. Petrucci, Bari
Which is why we ask which mass a document is reporting before we compare it with anything. The two figures differ by more than a dalton on a molecule of this size, and the difference has been read as an impurity more than once.
Any transposition of two residues preserves the intact mass exactly. So does a substitution that swaps one residue for another of the same composition. The set of molecules consistent with a given mass is not small, and describing a mass match as identity confirmation makes a claim about that whole set.
— C. Nightingale, Plymouth
The claim that a reproduced spectrum is worth more than any number in the document seems overstated. Most buyers cannot read a spectrum, and a printed image invites false confidence rather than scrutiny.
— A. Wiśniewski, Szczecin
Partly conceded. A spectrum is worth more to a reader who can read one, and this department exists partly to increase that number. But it is also an artefact that can be checked by a third party later, which a bare verdict is not, and that alone justifies printing it.
Reversed-phase chromatography runs in an organic, acidic mobile phase that dissociates most non-covalent aggregates on the way to the detector.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The ionisation method determines the charge states you see, the adducts you must account for, and the modifications you might destroy in the process.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
The result is unremarkable. What the report states alongside it is not.